Synthesis, Characterization and Biological Evaluation of Novel Dihydropyranoindoles Improving the Anticancer Effects of HDAC Inhibitors.
HDAC inhibitors
anticancer
breast cancer
dihydropyranoindole
neuroblastoma
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
18 Mar 2020
18 Mar 2020
Historique:
received:
28
02
2020
revised:
16
03
2020
accepted:
16
03
2020
entrez:
22
3
2020
pubmed:
22
3
2020
medline:
17
12
2020
Statut:
epublish
Résumé
The dihydropyranoindole scaffold was identified as a promising target for improving the anti-cancer activity of HDAC inhibitors from the preliminary screening of a library of compounds. A suitable methodology has been developed for the preparation of novel dihydropyranoindoles via the Hemetsberger indole synthesis using azido-phenylacrylates, derived from the reaction of corresponding alkynyl-benzaldehydes with methyl azidoacetate, followed by thermal cyclization in high boiling solvents. Anti-cancer activity of all the newly synthesized compounds was evaluated against the SH-SY5Y and Kelly neuroblastoma cells as well as the MDA-MB-231 and MCF-7 breast adenocarcinoma cell lines. Biological studies showed that the tetracyclic systems had significant cytotoxic activity at higher concentration against the neuroblastoma cancer cells. More importantly, these systems, at the lower concentration, considerably enhanced the SAHA toxicity. In addition to that, the toxicity of designated systems on the healthy human cells was found to be significantly less than the cancer cells.
Identifiants
pubmed: 32197360
pii: molecules25061377
doi: 10.3390/molecules25061377
pmc: PMC7144403
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Histone Deacetylase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Sci. 2008 Feb;99(2):376-84
pubmed: 18201278
Mar Drugs. 2011;9(10):1887-901
pubmed: 22073001
J Pediatr Hematol Oncol. 1999 May-Jun;21(3):181-9
pubmed: 10363850
J Clin Oncol. 2005 Jun 10;23(17):3923-31
pubmed: 15897550
J Thorac Cardiovasc Surg. 2004 Nov;128(5):740-8
pubmed: 15514602
Oncogene. 2007 Feb 26;26(9):1351-6
pubmed: 17322921
Cancer Chemother Pharmacol. 2011 Mar;67(3):705-15
pubmed: 20512578
Bioorg Med Chem. 2010 Dec 1;18(23):8243-56
pubmed: 21044845
PLoS One. 2012;7(7):e40816
pubmed: 22829886
Surgery. 2005 Aug;138(2):360-7
pubmed: 16153448
J Clin Oncol. 2007 Mar 20;25(9):1054-60
pubmed: 17369569
Clin Lung Cancer. 2006 Jan;7(4):257-61
pubmed: 16512979
J Clin Oncol. 2010 May 20;28(15):2625-34
pubmed: 20404250
Invest New Drugs. 2005 Mar;23(2):99-109
pubmed: 15744585
Mol Cancer Ther. 2010 Dec;9(12):3289-301
pubmed: 21159612
Bioorg Med Chem Lett. 2009 Dec 15;19(24):7003-6
pubmed: 19879136
Clin Cancer Res. 2007 Apr 15;13(8):2318-22
pubmed: 17438089
J Clin Oncol. 2009 Mar 1;27(7):1020-5
pubmed: 19171714